Objective:？The objective of the study was to determine the survival of patients？with small-cell lung cancer treated at tertiary hospitals in the East of？Thailand. Materials and methods:？The researchers conducted this retrospective？study by reviewing medical records of patients with small-cell lung cancer？treated at Chonburi Cancer Hospital and Prapokklao Hospital from January？2007 to December 2016 and monitored via follow-up until December？2018. Results:？This study enrolled 54 patients with a median follow-up time？of 8.5 months. The median age of patients was 63 years old. Most patients？were male (83.3%) and had a history of smoking (90.7%), and 31.4% had？clinical superior vena cava obstruction at initial treatment. The Eastern Cooperative？Oncology Group performance status 0-1 was noted for 61.1% of the？study population. Median survival time of patients with limited-stage and extensive-stage small cell lung cancer who received systemic chemotherapy？and/or radiotherapy was 17.01 months (95% CI, 12.01 - 22.01) and 8.14？months (95% CI, 7.19 - 9.10), respectively, and that of patients
References
[1]
International Agency Research on Cancer (2018) World Health Organization. Globocan 2018.
https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
[2]
Govindan, R., Page, N., Morgensztern, D., et al. (2006) Changing Epidemiology of Small-Cell Lung Cancer in the United States over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database. Journal of Clinical Oncology, 24, 4539-4544. https://doi.org/10.1200/JCO.2005.04.4859
[3]
Khakwani, A., Rich, A.L., Tata, L.J., et al. (2014) Small-Cell Lung Cancer in England: Trends in Survival and Chemotherapy Using the National Lung Cancer Audit. PLoS ONE, 9, e89426. https://doi.org/10.1371/journal.pone.0089426
[4]
Chang, J.T., Jeon, J., Sriplung, H., et al. (2018) Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014. Journal of Global Oncology, 4, 1-29. https://doi.org/10.1200/JGO.18.00013
[5]
Jett, J.R., Schild, S.E., Kesler, K.A. and Kalemkerian, G.P. (2013) Treatment of Small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143, e400S-e419S. https://doi.org/10.1378/chest.12-2363
[6]
Horn, L., Mansfield, A.S., Szczesna, A., et al. (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. The New England Journal of Medicine, 379, 2220-2229. https://doi.org/10.1056/NEJMoa1809064
[7]
Turrisi, A.T., Kim, K., Blum, R., et al. (1999) Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide. The New England Journal of Medicine, 340, 265-271.
https://doi.org/10.1056/NEJM199901283400403
[8]
Takada, M., Fukuoka, M., Kawahara, M., et al. (2002) Phase III Study of Concurrent versus Sequential Thoracic Radiotherapy in Combination with Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104. Journal of Clinical Oncology, 20, 3054-3060.
https://doi.org/10.1200/JCO.2002.12.071
[9]
Faivre-Finn, C., Snee, M., Ashcroft, L., et al. (2017) Concurrent Once-Daily versus Twice-Daily Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer (CONVERT): An Open-Label, Phase 3, Randomised, Superiority Trial. The Lancet Oncology, 18, 1116-1125. https://doi.org/10.1016/S1470-2045(17)30318-2
[10]
Skarlos, D.V., Samantas, E., Briassoulis, E., et al. (2001) Randomized Comparison of Early versus Late Hyperfractionated Thoracic Irradiation Concurrently with Chemotherapy in Limited Disease Small-Cell Lung Cancer: A Randomized Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG). Annals of Oncology, 12, 1231-1238. https://doi.org/10.1023/A:1012295131640
[11]
Noda, K., Nishiwaki, Y., Kawahara, M., et al. (2002) Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer. The New England Journal of Medicine, 346, 85-91.
https://doi.org/10.1056/NEJMoa003034
[12]
Niell, H.B., Herndon, J.E., Miller, A.A., et al. (2005) Randomized Phase III Intergroup Trial of Etoposide and Cisplatin with or without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients with Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology, 23, 3752-3759. https://doi.org/10.1200/JCO.2005.09.071
[13]
Lara Jr., P.N., Natale, R., Crowley, J., et al. (2009) Phase III Trial of Irinotecan/Cisplatin Compared with Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results from SWOG S0124. Journal of Clinical Oncology, 27, 2530-2535. https://doi.org/10.1200/JCO.2008.20.1061
[14]
Hermes, A., Bergman, B., Bremnes, R., et al. (2008) Irinotecan plus Carboplatin versus Oral Etoposide plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial. Journal of Clinical Oncology, 26, 4261-4267.
https://doi.org/10.1200/JCO.2007.15.7545
[15]
Kuo, Y.H., Lin, Z.Z., Yang, Y.Y., et al. (2012) Survival of Patients with Small Cell Lung Carcinoma in Taiwan. Oncology, 82, 19-24.
https://doi.org/10.1159/000335084
[16]
Pezzi, T.A., Schwartz, D.L., Mohamed, A.S.R., et al. (2017) Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer. JAMA Oncology, 4, e174504. https://doi.org/10.1001/jamaoncol.2017.4504
[17]
Steffens, C.C., Elender, C., Hutzschenreuter, U., et al. (2019) Treatment and Outcome of 432 Patients with Extensive-Stage Small Cell Lung Cancer in First, Second and Third Line-Results from the Prospective German TLK Cohort Study. Lung Cancer, 130, 216-225. https://doi.org/10.1016/j.lungcan.2019.02.026
[18]
National Comprehensive Cancer Network (2019) Small Cell Lung Cancer, Version 1. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
[19]
Wilson, L.D., Detterbeck, F.C. and Yahalom, J. (2007) Clinical Practice. Superior Vena Cava Syndrome with Malignant Causes. The New England Journal of Medicine, 356, 1862-1869. https://doi.org/10.1056/NEJMcp067190
[20]
Johnson, B.E., Chute, J.P., Rushin, J., et al. (1997) A Prospective Study of Patients with Lung Cancer and Hyponatremia of Malignancy. American Journal of Respiratory and Critical Care Medicine, 156, 1669-1678.
https://doi.org/10.1164/ajrccm.156.5.96-10075
[21]
National Comprehensive Cancer Network (2019) NCCN Chemotherapy Order Templates (NCCN Templates®). Appendix B: Carboplatin Dosing.
https://www.nccn.org/professionals/OrderTemplates/PDF/appendix_B.pdf
[22]
Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247. https://doi.org/10.1016/j.ejca.2008.10.026
[23]
Sculier, J.P., Evans, W.K., Feld, R., et al. (1986) Superior Vena Caval Obstruction Syndrome in Small Cell Lung Cancer. Cancer, 57, 847-851.
https://doi.org/10.1002/1097-0142(19860215)57:4<847::AID-CNCR2820570427>3.0.CO;2-H
[24]
Thunnissen, E., Borczuk, A.C., Flieder, D.B., et al. (2017) The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. Journal of Thoracic Oncology, 12, 334-346.
https://doi.org/10.1016/j.jtho.2016.12.004
[25]
Travis, W.D. (2010) Advances in Neuroendocrine Lung Tumors. Annals of Oncology, 21, vii65-vii71. https://doi.org/10.1093/annonc/mdq380
[26]
Shepherd, F.A., Crowley, J., Houtte, P., et al. (2007) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer. Journal of Thoracic Oncology, 2, 1067-1077. https://doi.org/10.1097/JTO.0b013e31815bdc0d
[27]
Jeremic, B., Shibamoto, Y., Nikolic, N., et al. (1999) Role of Radiation Therapy in the Combined-Modality Treatment of Patients with Extensive Disease Small-Cell Lung Cancer: A Randomized Study. Journal of Clinical Oncology, 17, 2092-2099.
https://doi.org/10.1200/JCO.1999.17.7.2092
[28]
Slotman, B.J., van Tinteren, H., Praag, J.O., et al. (2015) Use of Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Phase 3 Randomised Controlled Trial. The Lancet, 385, 36-42. https://doi.org/10.1016/S0140-6736(14)61085-0
[29]
Denton, E. and Conron, M. (2016) Improving Outcomes in Lung Cancer: The Value of the Multidisciplinary Health Care Team. Journal of Multidisciplinary Healthcare, 9, 137-144. https://doi.org/10.2147/JMDH.S76762
[30]
Minami, S., Ogata, Y., Ihara, S., Yamamoto, S. and Komuta, K. (2016) Retrospective Analysis of Outcomes and Prognostic Factors of Chemotherapy for Small-Cell Lung Cancer. Lung Cancer: Targets and Therapy, 7, 35-44.
https://doi.org/10.2147/LCTT.S100184
